Evidence mapPaperPMID 26157708Full record

ArticleJournal of diabetes and metabolic disorders2015

Targeting metabolic disorders by natural products.

Ozra Tabatabaei-Malazy, Bagher Larijani, Mohammad Abdollahi

Open access · hybridAbstract read
In one paragraph

Article in Journal of diabetes and metabolic disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.

  1. Withdrawal reasons of randomized controlled trials on type 2 diabetes: a systematic review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2021
    Pooled it
  2. Article
  3. Article
  4. Synergistic Effect ofBiomolecules · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. The Herbal Blend ofFoods (Basel, Switzerland) · 2024
    Article
  9. Licochalcone D fromInternational journal of molecular sciences · 2024
    Article
  10. Mitigating Effects ofPlants (Basel, Switzerland) · 2024
    Article
  11. Review
  12. Gut microbiota in insulin resistance: a bibliometric analysis.Journal of diabetes and metabolic disorders · 2024
    Review
  13. Postbiotics as Metabolites and Their Biotherapeutic Potential.International journal of molecular sciences · 2024
    Review
  14. Article
  15. Review
  16. Heliyon · 2024
    Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ozra Tabatabaei-MalazyDiabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Bagher Larijani *Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Abdollahi *Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most prevalent metabolic disorders are diabetes mellitus, obesity, dyslipidemia, osteoporosis and metabolic syndrome, which are developed when normal metabolic processes are disturbed. The most common pathophysiologies of the above disorders are oxidative stress, Nrf2 pathways, epigenetic, and change in miRNA expression. There is a challenge in the prevention and treatment of metabolic disorders due to severe adverse effects of some synthetic drugs, their high cost, lack of safety and poverty in some conditions, and insufficient accessibility for the general population in the world. With increasing interest in shifting from synthetic drugs to phytotherapy as an alternative treatment, there is still a gap in scientific evidences of plant-derived therapeutic benefits. One reason may be slow rate of translation of animal studies' findings into human clinical trials. Since metabolic disorders are multifactorial, it seems that poly-herbal medications, or drug-herbal combination are needed for their treatment. However, further researches to determine the most effective plant-derived metabolites, and their cellular mechanism in order to set priorities for well-designed animal and clinical trials, and also more studies with strong scientific evidences such as systematic review and meta-analysis of controlled studies are needed.

Indexed as

EpigeneticMetabolic disordersNatural productsOxidative stress

Identifiers

PMID26157708
PMCPMC4495701
OpenAlexW1504250785

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.